Quadrucept Bio. Ltd.

Quadrucept bio. ltd. email format

Verified email-pattern data for Quadrucept Bio. Ltd. is currently limited. You can still use the company insights and contact sections below.
Founded by Kymab's former leadership team (acquired by Sanofi in 2021) Quadrucept's QUAD Technology Empowers the Next-Generation of Antibody-based Drugs:- - Super Antagonists: From new or existing Fab or VHH domains - Superior “Receptor Bodies”: High avidity receptor-Fc fusion decoy molecules - Potent Antibody Agonists: Multivalent Fab/VHH receptor clustering - Improved Target Selectivity: Tetravalent low-affinity high-avidity binding - Pioneering Bi-Specifics: Flexible formats tailored for every need - Fc-Multi-valency: Enabling “best-in-class” half-life extension - “One-Two Punch” ADCs: Avidity-driven targeting-Greater payload capacity - Simplicity: Highly efficient self-assembly of monomeric building blocks - Standard Manufacturing: High expression, stability, drug-like properties - Broad and Early Patent Estate: First to the field – All therapeutic targets
Looking for a particular Quadrucept Bio. Ltd. employee's phone or email?

Quadrucept Bio. Ltd. Questions

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant